Kalaris Therapeutics Inc
KLRS
Company Profile
Business description
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
Contact
628 Middlefield Road
Palo AltoCA94301
USAT: +1 650 249-2727
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
Stocks News & Analysis
stocks
Apple: Gemini partnership lets AI-worried investors breathe a sigh of relief
We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,184.20 | 27.30 | -0.30% |
| CAC 40 | 8,310.84 | 20.12 | -0.24% |
| DAX 40 | 25,300.77 | 14.53 | 0.06% |
| Dow JONES (US) | 49,391.55 | 241.92 | 0.49% |
| FTSE 100 | 10,244.02 | 59.67 | 0.59% |
| HKSE | 26,923.62 | 76.19 | -0.28% |
| NASDAQ | 23,646.65 | 174.90 | 0.75% |
| Nikkei 225 | 54,110.50 | 230.73 | -0.42% |
| NZX 50 Index | 13,659.79 | 97.92 | -0.71% |
| S&P 500 | 6,962.69 | 36.09 | 0.52% |
| S&P/ASX 200 | 8,861.70 | 19.30 | -0.22% |
| SSE Composite Index | 4,112.60 | 13.49 | -0.33% |